The principles and policies of transparency of TCP were first prepared in Aug 2017 in order to conform to the Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by COPE (https://publicationethics.org), DOAJ, WAME, and OASPA.
1. Peer review process: Except for invited manuscripts, all the manuscripts submitted to TCP should be peer reviewed for publication. The peer review process is described in the “Instruction for Authors”. The peer reviewers should be experts on the related disciplines and they should not be editorial board members of TCP for fairness. TCP clarifies whether the manuscript was peer reviewed or not on the front page of each article. The reviewer must disclose any conflicts of interest that could bias their opinions of the manuscript when accepting the proposal to review and submit their review comments within four weeks. Reviewers must not use knowledge of the work they’re reviewing before its publication to further their own interests.
2. Governing Body: The editorial board of TCP consists of editor-in-chief (EIC, publication director of KSCPT) and editors who are experts in clinical pharmacology and related translational science.
3. Editorial team/contact information: The full names and affiliations of the editors and contact information for the editorial office of TCP are provided at “Editors” section of our journal homepage.
4. Author fees: The author fee charged per manuscript is 290 US $ or 300,000 KRW except for invited articles. In case of bioequivalence report or PMS report, the author fee is 1,900 US $ or 2 million KRW. The invoice will be sent to the author after acceptance of the manuscript. Invited articles are exempted from the fee.
5. Copyright: Copyright of articles belongs to TCP except for the invited ones whose copyright is owned by the authors. Regardless of the copyright owner, all the articles published in TCP are distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. For the commercial use of articles, contact the EIC of TCP.
6. Process for identification of and dealing with allegations of research misconduct: Currently, all of the manuscripts submitted to TCP are screened to prevent plagiarism using a similarity check system ( https://crosscheck.ithenticate.com before allocation for peer review. The editors continually monitor the review process to prevent citation manipulation by peer reviewers or editors. In the case of suspected redundant publication, data fabrication/ falsification, authorship disputes or any other research misconduct in submitted manuscripts or published articles in TCP, the editors will follow latest COPE’s flow charts.
7. Ownership and management: TCP is the official journal of the Korean Society for Clinical Pharmacology and Therapeutics.
8. Web site: The contents in this website (www.tcpharm.org) does not contain any misleading information, or any attempt to mimic another journal/publisher’s site.
9. Name of journal: The journal name (Translational and clinical pharmacology) was decided by the editorial committee of KSCPT gathered to convert its official journal “Journal of Korean Society for Clinical Pharmacology and Therapeutics” (Korean) which had been issued since 1993 to a full English journal in 2014.
10. Conflicts of interest: The conflicts of interest (COI) of authors are declared in the manuscript. Peer reviewers are requested to declare COI when they submit their review opinions. In the published article, the COI of reviewers and editors if any are also declared together with those of authors. The editors will follow the latest flowcharts of COPE in case of suspected undisclosed COI in manuscripts or published articles. When associate editors submit uninvited manuscripts, the EIC will allocate the manuscript to another editor who is not one of the authors. When the EIC submits his/her own manuscripts, the EIC should allocate it to one of associate editors and the associate editor’s decision on that manuscript is final. The EIC cannot interfere or influence the decision process.
11. Access: TCP is an open access journal and its contents are available at the journal homepage and Synapse (https://synapse.koreamed.org).
12. Revenue sources: The budget of TCP publication come from the author fee, advertising and supports from the KSCPT.
13. Advertising: The adverts at printed or online versions are welcomed unless they are found against the value of KSCPT. The adverts are pre-screened by the chairperson of the board of directors of KSCPT. Accepting of the adverts and their placement (links to the contents or position in the web pages) are decided by the EIC. Accepting of the adverts and their placement (links to the contents or position in the web pages) are decided by the EIC.
14. Publishing schedule: TCP is published every three months (15 of Mar, June, Sep and Dec).
15. Archiving: Even in the event that TCP is no longer published, the archives are permanently accessible at its current homepage and the digital archive of KAMJE(https://synapse.koreamed.org).
16. Direct marketing activities: Random solicitation of manuscripts will not be conducted. The editor-in-chief may announce the contents of articles published in TCP via researchers’ networks.